1. Home
  2. CDNA vs EOS Comparison

CDNA vs EOS Comparison

Compare CDNA & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.44

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Enhance Equity Income Fund II

EOS

Eaton Vance Enhance Equity Income Fund II

HOLD

Current Price

$21.80

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
EOS
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CDNA
EOS
Price
$19.44
$21.80
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$26.67
N/A
AVG Volume (30 Days)
656.6K
84.1K
Earning Date
02-24-2026
01-01-0001
Dividend Yield
N/A
6.80%
EPS Growth
N/A
N/A
EPS
1.22
N/A
Revenue
$357,998,000.00
N/A
Revenue This Year
$14.49
N/A
Revenue Next Year
$11.32
N/A
P/E Ratio
$16.16
N/A
Revenue Growth
14.46
N/A
52 Week Low
$10.96
$15.62
52 Week High
$25.55
$20.63

Technical Indicators

Market Signals
Indicator
CDNA
EOS
Relative Strength Index (RSI) 48.29 36.37
Support Level $18.81 $21.57
Resistance Level $21.00 $22.50
Average True Range (ATR) 1.11 0.33
MACD -0.13 -0.03
Stochastic Oscillator 40.03 21.03

Price Performance

Historical Comparison
CDNA
EOS

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About EOS Eaton Vance Enhance Equity Income Fund II

Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.

Share on Social Networks: